As a countermeasure, RV was found to trigger proteasomal degradation of AGO2, the catalytic effector of the siRNA‐mediated RNAi in mammalian cells, during the early hours of infection, leading to the loss-of functionality of siRNA-based RNAi (Mukhopadhyay et al., 2019b). The gene discussed is AGO2; the disease is infection.